Picture Kentro Design Is Key to Your Success Berlin 650x100px
Document › Details

Core Biogenesis SAS. (7/28/22). "Press Release: Core Biogenesis Raises $10.5M to Accelerate Plant-Based Bioproduction". Strasbourg.

Organisations Organisation Core Biogenesis SAS
  Organisation 2 Thia Ventures (CH, LU, BE, SG)
Products Product recombinant protein production in plant cells
  Product 2 venture capital
Index terms Index term Core Biogenesis–SEVERAL: investment, 202203 financing round Series A €10m led by XAnge + Blue Horizon Ventures
  Index term 2 Core Biogenesis–Thia Ventures: investment, 202203 financing round Series A totalling €10m incl new + co-investor Thia Ventures
Persons Person Reeber, Alexandre (Core Biogenesis 202204 CEO + Co-Founder)
  Person 2 Meziadi, Chouaib (Core Biogenesis 202204 CTO + Co-Founder)

Production facility for growth factors and cytokines launching in early 2023

Core Biogenesis, an emerging biotechnology company with a novel plant-based bioproduction platform, recently completed a $10.5M Series A funding round. The funds will be used to build out an industrial scale facility dedicated to producing growth factors and cytokines for the burgeoning cell therapy market and cellular agriculture industry, and to hire additional scientific and technical staff to support the expansion. The funding round was led by XAnge, a Paris-based science and technology venture capital firm. Other investors include Blue Horizon Ventures, a Zurich-based venture capital firm with a focus on protein alternatives and food tech, and Thia Ventures, an investor at the crossroads of biotechnology, nutrition and health, with offices in Geneva, Luxembourg, Belgium and Singapore.

Founded in May 2020, Core Biogenesis has developed a proprietary technology to express recombinant proteins from the seeds of the Camelina sativa oilseed plant. "Our patent-pending protein expression platform is a powerful tool for producing highly bioactive compounds in a completely animal-free and antibiotic-free manner," said CEO and Co-Founder Alexandre Reeber. "We achieve high yield while eliminating the biosafety risk of endotoxin, virus, and prion contamination seen with current mammalian and microbial expression platforms. After harvest, our downstream process is a simple three-step operation that achieves incredibly high purity."

While Core Biogenesis' molecular farming platform can be used to express recombinant growth factors for everything from therapeutics to cultivated meat, their first target is to address the complexity and high costs of next-generation therapeutic modalities such as cell therapies.

"The cell therapy market is at the forefront of future oncology, neurodegenerative disease, and personalized medicine treatments, with the market expected to grow from $9.2B in 2021 to $65B by 2027. Growth factors are critical cell culture media components and are widely employed in cell therapy manufacturing. We have generated stable lines expressing growth factors and cytokines at a high yield and have demonstrated that our products de-risk the cell expansion operation. Further, our technology drives down cell therapy manufacturing costs which will help to improve patient access to these life-saving therapies," explained Reeber. "Our large-scale recombinant protein production facility in Strasbourg will be fully functional in Q1 2023 and will ultimately have the capacity to produce kilograms of GMP-grade growth factors and cytokines."

"We hope to shift the bioprocessing field's mindset about recombinant protein production," added CSO and Co-Founder Chouaib Meziadi. "Not only can we produce proteins at high yield and lower cost than traditional methods, but our entire production process is carbon-negative. At Core Biogenesis, we truly believe that what is good for the patient can also be good for the planet."

As the company builds out the new manufacturing facility, they are also growing their team of scientific and technical experts to a total of 30 employees, with plans for additional expansions in the future.

About Core Biogenesis

Founded in May 2020 by Dr. Chouaib Meziadi and Alexandre Reeber, Core Biogenesis employs a novel green bioproduction platform to express recombinant proteins from plants. Their animal-free growth factors and cytokines contribute to a more cost-effective and commercially-viable cell therapy manufacturing process, thereby supporting the treatment of neurodegenerative and cardiovascular diseases and certain cancers. In December 2020, the startup raised €2.6 million in Seed from XAnge, Entrepreneur First, Plug and Play and several Business Angels. In March 2022 it completed a 2nd round of €10M in Series A from XAnge, Blue Horizon Ventures, Entrepreneur First and Business Angels. Core Biogenesis was Grand Prize winner of the national i-Lab BPI France competition in 2021.

Record changed: 2024-03-30


Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x200px

More documents for Core Biogenesis SAS

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner BIO 2024 International Convention San Diego 650x300px

» top